Genenta Science (GNTA) said Wednesday it received approval from the Italian Medicines Agency for a phase 1 clinical trial evaluating the company's drug Temferon in treating metastatic renal cell cancer.
The trial is expected to commence in Q4, Genenta said. It will target patients with a median overall survival that is currently less than 2 years after multiple lines of therapy, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments